AU2018451360B2 - Methods of treating myeloproliferative disorders - Google Patents

Methods of treating myeloproliferative disorders Download PDF

Info

Publication number
AU2018451360B2
AU2018451360B2 AU2018451360A AU2018451360A AU2018451360B2 AU 2018451360 B2 AU2018451360 B2 AU 2018451360B2 AU 2018451360 A AU2018451360 A AU 2018451360A AU 2018451360 A AU2018451360 A AU 2018451360A AU 2018451360 B2 AU2018451360 B2 AU 2018451360B2
Authority
AU
Australia
Prior art keywords
subject
isoxazolo
azepin
acetamide
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018451360A
Other languages
English (en)
Other versions
AU2018451360A1 (en
Inventor
Michael Cooper
Adrian SENDEROWICZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Constellation Pharmaceuticals Inc
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of AU2018451360A1 publication Critical patent/AU2018451360A1/en
Application granted granted Critical
Publication of AU2018451360B2 publication Critical patent/AU2018451360B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018451360A 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders Active AU2018451360B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (2)

Publication Number Publication Date
AU2018451360A1 AU2018451360A1 (en) 2021-06-10
AU2018451360B2 true AU2018451360B2 (en) 2022-05-26

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018451360A Active AU2018451360B2 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Country Status (8)

Country Link
JP (2) JP7453230B2 (enExample)
KR (2) KR102738936B1 (enExample)
AU (1) AU2018451360B2 (enExample)
BR (1) BR112021010134A2 (enExample)
CA (1) CA3120973A1 (enExample)
EA (1) EA202191489A1 (enExample)
SG (1) SG11202105279SA (enExample)
WO (1) WO2020112086A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006205A (es) 2018-11-27 2021-10-13 Constellation Pharmaceuticals Inc Metodos de tratamiento de trastornos mieloproliferativos.
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
EP4192470A1 (en) * 2020-08-04 2023-06-14 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating thrombocythemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
SI3157928T1 (sl) 2014-06-20 2019-06-28 Constellation Pharmaceuticals, Inc. Kristalinične oblike 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo(C)izoksazolo(4,5-E)azepin-4-il acetamida

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anonymous, "CPI-0610 receives fast track designation for MF MDedge Hematology and Oncology", (2018-11-06), URL: https://www.mdedge.com/hematology-oncology/article/184600/cythemias/cpi-0610-receives-fast-track-designation-mf, (2019-07-22) *
BRIAN K. ALBRECHT ET AL, JOURNAL OF MEDICINAL CHEMISTRY, US, (2016-02-04), vol. 59, no. 4, doi:10.1021/acs.jmedchem.5b01882, ISSN 0022-2623, pages 1330 - 1339 *
Marina Kremyanskaya, "A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF) Blood Journal", (2018-11-21), URL: http://www.bloodjournal.org/content/132/Suppl_1/5481, (2019-07-22) *
US National Library of Medicine ClinicalTrials.gov archive'History of Changes for Study: NCT02158858." (published on 22 November 2016) [retreived08 March 2022] *

Also Published As

Publication number Publication date
KR20210095904A (ko) 2021-08-03
WO2020112086A1 (en) 2020-06-04
SG11202105279SA (en) 2021-06-29
CA3120973A1 (en) 2020-06-04
JP7453230B2 (ja) 2024-03-19
KR20250004357A (ko) 2025-01-07
EA202191489A1 (ru) 2021-09-10
KR102738936B1 (ko) 2024-12-06
JP2024063214A (ja) 2024-05-10
JP2022519425A (ja) 2022-03-24
AU2018451360A1 (en) 2021-06-10
BR112021010134A2 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
US12070464B2 (en) Methods of treating myeloproliferative disorders
AU2018451360B2 (en) Methods of treating myeloproliferative disorders
JP2021119162A (ja) 肝疾患の予防および治療のための薬物の調製におけるトリメタジジンの使用
KR20180124055A (ko) 급성 골수성 백혈병의 치료를 위한 병용 요법
WO2021091535A1 (en) Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2021091532A1 (en) Methods of treating myeloproliferative disorders
EP4337213A1 (en) Use of pelabresib for treating anemias
WO2020256739A1 (en) Methods of treating myeloproliferative disorders
KR20230110751A (ko) 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제
EA047870B1 (ru) Способы лечения миелопролиферативных расстройств
WO2020257644A1 (en) Methods of treating myeloproliferative disorders
WO2025096692A2 (en) Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
EA050232B1 (ru) Способы лечения анемий
US20230302010A1 (en) 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating thrombocythemia
TW202432141A (zh) 治療骨髓增生性腫瘤的方法
Wei et al. Hematopoietic Cell Kinase (HCK) Is a Key Regulator of Macrophage Function in Kidney Fibrosis: FR-PO959
WO2025002346A1 (zh) 含pd-l1小分子抑制剂的药物组合及其应用
WO2024192139A1 (en) Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
CN117442738A (zh) 一种联合用药物组合物在制备预防或治疗t细胞淋巴瘤的药物中的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)